Just prior to Bayer AG’s capital market day in London in December 2018, the pharma giant surprised some with an announcement that the company was planning a major restructuring. Find out the details of the various measures this streamlining process will take, the rationale behind some of the moves being made, including its exit from the animal health market, the projected cost-savings it’s expected to produce, and how analysts are reacting to the plans in this informative article from Scrip.